Javascript must be enabled to continue!
Data from Preconditioned Endothelial Progenitor Cells Reduce Formation of Melanoma Metastases through SPARC-Driven Cell–Cell Interactions and Endocytosis
View through CrossRef
<div>Abstract<p>Tumor progression is associated with the release of signaling substances from the primary tumor into the bloodstream. Tumor-derived cytokines are known to promote the mobilization and the recruitment of cells from the bone marrow, including endothelial progenitor cells (EPC). Here, we examined whether such paracrine influence could also influence the capacity of EPC to interfere with circulating metastatic cells. We therefore consecutively injected EPC prestimulated by tumor-conditioned medium (EPC-CM) and luciferase-expressing B16 melanoma cells to mice. A net decrease in metastases spreading (vs. nonstimulated EPC) led us to carry out a 2-dimensional difference gel electrophoresis (2D-DIGE) proteomic study to identify possible mediators of EPC-driven protection. Among 33 proteins exhibiting significant changes in expression, secreted protein, acidic and rich in cysteine (SPARC) presented the highest induction after EPC exposure to CM. We then showed that contrary to control EPC, SPARC-silenced EPC were not able to reduce the extent of metastases when injected with B16 melanoma cells. Using adhesion tests and the hanging drop assay, we further documented that cell–cell interactions between EPC-CM and melanoma cells were promoted in a SPARC-dependent manner. This interaction led to the engulfment of melanoma cells by EPC-CM, a process prevented by SPARC silencing and mimicked by recombinant SPARC. Finally, we showed that contrary to melanoma cells, the prometastatic human breast cancer cell line MDA-MB231-D3H2 reduced SPARC expression in human EPC and stimulated metastases spreading. Our findings unravel the influence of tumor cells on EPC phenotypes through a SPARC-driven accentuation of macrophagic capacity associated with limitations to metastatic spread. <i>Cancer Res; 71(14); 4748–57. ©2011 AACR</i>.</p></div>
American Association for Cancer Research (AACR)
Title: Data from Preconditioned Endothelial Progenitor Cells Reduce Formation of Melanoma Metastases through SPARC-Driven Cell–Cell Interactions and Endocytosis
Description:
<div>Abstract<p>Tumor progression is associated with the release of signaling substances from the primary tumor into the bloodstream.
Tumor-derived cytokines are known to promote the mobilization and the recruitment of cells from the bone marrow, including endothelial progenitor cells (EPC).
Here, we examined whether such paracrine influence could also influence the capacity of EPC to interfere with circulating metastatic cells.
We therefore consecutively injected EPC prestimulated by tumor-conditioned medium (EPC-CM) and luciferase-expressing B16 melanoma cells to mice.
A net decrease in metastases spreading (vs.
nonstimulated EPC) led us to carry out a 2-dimensional difference gel electrophoresis (2D-DIGE) proteomic study to identify possible mediators of EPC-driven protection.
Among 33 proteins exhibiting significant changes in expression, secreted protein, acidic and rich in cysteine (SPARC) presented the highest induction after EPC exposure to CM.
We then showed that contrary to control EPC, SPARC-silenced EPC were not able to reduce the extent of metastases when injected with B16 melanoma cells.
Using adhesion tests and the hanging drop assay, we further documented that cell–cell interactions between EPC-CM and melanoma cells were promoted in a SPARC-dependent manner.
This interaction led to the engulfment of melanoma cells by EPC-CM, a process prevented by SPARC silencing and mimicked by recombinant SPARC.
Finally, we showed that contrary to melanoma cells, the prometastatic human breast cancer cell line MDA-MB231-D3H2 reduced SPARC expression in human EPC and stimulated metastases spreading.
Our findings unravel the influence of tumor cells on EPC phenotypes through a SPARC-driven accentuation of macrophagic capacity associated with limitations to metastatic spread.
<i>Cancer Res; 71(14); 4748–57.
©2011 AACR</i>.
</p></div>.
Related Results
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity
Abstract
Purpose
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and lacks specific targeted ...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel
Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel
618 Background: Neoadjuvant combinations of gemcitabine (G), anthracyclines and taxanes have demonstrated substantial activity with pCR rates of 20–25%. Secreted protein acidic ri...
Abstract 2495: SPARC: a bladder cancer tumor-suppressor via targeting metabolic programming
Abstract 2495: SPARC: a bladder cancer tumor-suppressor via targeting metabolic programming
Abstract
Bladder cancer (BC) is the sixth most common cancer in the United States. Approximately, 75% of BC patients present with non-muscle invasive bladder cancer ...
KnowMore: an automated knowledge discovery tool for the FAIR SPARC datasets
KnowMore: an automated knowledge discovery tool for the FAIR SPARC datasets
Abstract
This manuscript provides the methods and outcomes of KnowMore, the Grand Prize winning automated knowledge discovery tool developed by o...
Abstract POSTER-BIOL-1344: Epigenetic regulation of SPARC in ovarian cancer
Abstract POSTER-BIOL-1344: Epigenetic regulation of SPARC in ovarian cancer
Abstract
Background: We have previously reported the tumor suppressor effect of Secreted protein acidic and rich in cysteine (SPARC) in ovarian cancer in vitro and i...
KnowMore: an automated knowledge discovery tool for the FAIR SPARC datasets
KnowMore: an automated knowledge discovery tool for the FAIR SPARC datasets
Background:
This manuscript provides the methods and outcomes of KnowMore, the Grand Prize winning automated knowledge discovery tool developed by our team duri...
Abstract 1654: Cisplatin resistance is associated with autophagy in SPARC expressing medulloblastoma cells.
Abstract 1654: Cisplatin resistance is associated with autophagy in SPARC expressing medulloblastoma cells.
Abstract
Medulloblastoma is the most common malignant brain tumor in children and is associated with a poor outcome. Our previous studies indicate that SPARC express...

